Literature DB >> 2424991

Structural relationships between the DR beta 1 and DR beta 2 subunits in DR4, 7, and w9 haplotypes and the DRw53 (MT3) specificity.

T Matsuyama, J Schwenzer, J Silver, R Winchester.   

Abstract

The class II molecules of DR4, DR7, and DRw9 haplotypes were analyzed by immunoprecipitation, followed by two-dimensional gel electrophoresis and N-terminal amino acid sequencing. By using HLA-DR chain-specific monoclonal antibodies, two distinct DR beta-chains were identified. One beta-chain, designated DR beta 2, had a characteristic acidic mobility. In all three DR types the DR beta 2-chains were indistinguishable by two-dimensional gel electrophoresis and partial N-terminal sequencing. A second DR beta-chain designated beta 1 had a more basic mobility on two-dimensional gel electrophoresis, and differed from the DR beta 2-chains by the consistent presence of phenylalanine at position 18. In contrast to the DR beta 2-chains, the DR beta 1-chains were clearly polymorphic, with specific amino acid sequence differences characteristic of each DR type. The monoclonal antibodies 109d6 and 17-3-3S, recognizing distinct polymorphic epitopes similarly correlated with the DRw53 allospecificity, were found to react with different DR beta-chains. The epitope recognized by monoclonal antibody 109d6 was identified on the DR beta 2-chain in the prototypic DR4, DR7, and DRw9 cell lines. However, the DR7, Dw11, DQw3 cell line BEI was unreactive with antibody 109d6 by either immunofluorescence or immunoprecipitation despite the presence of the DRw53 allodeterminant on this cell line. The other DRw53-like monoclonal antibody, 17-3-3S, reacted with the DR beta 1-rather than the DR beta 2-chain in all DR4 and DR7 cell lines tested, including the cell line BEI. However, antibody 17-3-3S did not react with the DRw53-positive DRw9 cell line ISK. These studies suggest that the DRw53 allospecificity is more complex than previously thought and may comprise a number of distinct epitopes encoded by two different DR beta loci.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424991

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Molecular analysis of the MHC class II region in DR4, DR7, and DR9 haplotypes.

Authors:  E Kendall; J A Todd; R D Campbell
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

Review 2.  The molecular basis of susceptibility to rheumatoid arthritis: the conformational equivalence hypothesis.

Authors:  R J Winchester; P K Gregersen
Journal:  Springer Semin Immunopathol       Date:  1988

3.  Polymorphism of HLA-DR beta chains in DR4, -7, and -9 haplotypes: implications for the mechanisms of allelic variation.

Authors:  P K Gregersen; T Moriuchi; R W Karr; F Obata; J Moriuchi; J Maccari; D Goldberg; R J Winchester; J Silver
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 4.  Susceptibility genetics of systemic lupus erythematosus.

Authors:  H H Shen; R J Winchester
Journal:  Springer Semin Immunopathol       Date:  1986

5.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.

Authors:  R M Chicz; R G Urban; J C Gorga; D A Vignali; W S Lane; J L Strominger
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

6.  Identification of the sequence required for expression of the 2H4 epitope on the human leukocyte common antigens.

Authors:  M Streuli; T Matsuyama; C Morimoto; S F Schlossman; H Saito
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

7.  Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex.

Authors:  T Matsuyama; A Yamada; J Kay; K M Yamada; S K Akiyama; S F Schlossman; C Morimoto
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.